Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Obesity

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 104 articles: HTML format

Single Articles

October 2026
1. ROTH CL, Miller JL
   Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.
   N Engl J Med. 2026;395:1563-1564.
   PubMed    
   
   
   
2. OU Q, Tang J
   Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
   N Engl J Med. 2026;395:1563.
   PubMed    
   
   
   
3. ZHANG J, Zhan X, Li T
   Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
   N Engl J Med. 2026;395:1562-1563.
   PubMed    
   
   
   
4. SCHMITZ SH
   Beyond Percentage of Weight Lost - Protecting Participants in Obesity Trials.
   N Engl J Med. 2026;395:1355-1357.
   PubMed    
   
   
   
5. WHARTON S, le Roux CW, Startseva E, Kloer IM, et al
   Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
   N Engl J Med. 2026 Oct 1. doi: 10.1056/NEJMoa2607219.
   PubMed     Abstract available
   
   
   September 2026
6. JASTREBOFF AM, Kaplan LM, Davies MJ, Wilding JPH, et al
   Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
   N Engl J Med. 2026 Sep 29. doi: 10.1056/NEJMoa2604169.
   PubMed     Abstract available
   
   
   
7. XIE SH, Smyth E, Lagergren J
   Esophageal Cancer.
   N Engl J Med. 2026;395:1100-1111.
   PubMed     Abstract available
   
   
   July 2026
8. FAROOQI IS
   Treating Acquired Hypothalamic Obesity.
   N Engl J Med. 2026;395:190-193.
   PubMed    
   
   
   
9. MILLER JL, van Santen HM, Phillips SA, Hamilton J, et al
   Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
   N Engl J Med. 2026;395:138-150.
   PubMed     Abstract available
   
   
   June 2026
10. LE ROUX CW, Wharton S, Startseva E, Kloer IM, et al
    Survodutide Once Weekly for the Treatment of Adults with Obesity.
    N Engl J Med. 2026 Jun 7. doi: 10.1056/NEJMoa2600751.
    PubMed     Abstract available
    
    
    April 2026
11. ROSEN CJ, Ingelfinger JR
    GLP-1 Receptor Agonists.
    N Engl J Med. 2026;394:1313-1324.
    PubMed     Abstract available
    
    
    December 2025
12. WHARTON S, Duque do Vale R, Garvey WT
    Oral Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2025;393:2383.
    PubMed    
    
    
    
13. LIU H, Sun F, Wu J
    Oral Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2382.
    PubMed    
    
    
    
14. KERMANSARAVI M, Cohen RV
    Oral Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2381-2382.
    PubMed    
    
    
    
15. JASTREBOFF AM, Ryan DH, Pannacciulli N
    Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply.
    N Engl J Med. 2025;393:2275.
    PubMed    
    
    
    
16. MUSKIET MHA, Smits MM
    Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
    N Engl J Med. 2025;393:2274-2275.
    PubMed    
    
    
    
17. LIU QK
    Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial.
    N Engl J Med. 2025;393:2274.
    PubMed    
    
    
    November 2025
18. DAVIES MJ, Broholm C, Garvey WT
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2025;393:2067-2068.
    PubMed    
    
    
    
19. GARVEY WT, Osorto Contreras CK, Davies MJ
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
    N Engl J Med. 2025;393:2067.
    PubMed    
    
    
    
20. CHI H, Yang H, Deng Y
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2067.
    PubMed    
    
    
    
21. LNU V, Noor F
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2066-2067.
    PubMed    
    
    
    
22. KRAKAUER JC, Krakauer NY
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2066.
    PubMed    
    
    
    
23. FOGACCI F, Cicero AFG
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:2065-2066.
    PubMed    
    
    
    October 2025
24. ARONNE LJ
    Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.
    N Engl J Med. 2025;393:1655-1656.
    PubMed    
    
    
    
25. ABDULLAYEV N, Sanduleanu S
    Tirzepatide vs. Semaglutide for Obesity Treatment.
    N Engl J Med. 2025;393:1655.
    PubMed    
    
    
    
26. MUSKIET MHA, Winter EM, Rensen PCN
    Tirzepatide vs. Semaglutide for Obesity Treatment.
    N Engl J Med. 2025;393:1654-1655.
    PubMed    
    
    
    September 2025
27. WHARTON S, Lingvay I, Bogdanski P, Duque do Vale R, et al
    Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
    N Engl J Med. 2025;393:1077-1087.
    PubMed     Abstract available
    
    
    
28. WHARTON S, Aronne LJ, Stefanski A, Alfaris NF, et al
    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
    N Engl J Med. 2025 Sep 16. doi: 10.1056/NEJMoa2511774.
    PubMed     Abstract available
    
    
    
29. JI L, Qian L
    Once-Weekly Mazdutide in Obesity or Overweight. Reply.
    N Engl J Med. 2025;393:10.
    PubMed    
    
    
    
30. ZHANG Y, Yu L, Liu ZT
    Once-Weekly Mazdutide in Obesity or Overweight.
    N Engl J Med. 2025;393:10.
    PubMed    
    
    
    August 2025
31. KOTANIDIS CP, Lincoff AM, Shikora SA
    Managing Obesity.
    N Engl J Med. 2025;393:719-721.
    PubMed    
    
    
    
32. HALES CM
    Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care.
    N Engl J Med. 2025;393:712-714.
    PubMed    
    
    
    July 2025
33. GREENWAY FL
    Semaglutide and Tirzepatide to Treat Obesity.
    N Engl J Med. 2025;393:84-85.
    PubMed    
    
    
    June 2025
34. JASTREBOFF AM, Bunck MC, Ahmad NN
    Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
    N Engl J Med. 2025;392:2492-2493.
    PubMed    
    
    
    
35. SHUKLA AK, Bhavya B
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2492.
    PubMed    
    
    
    
36. BIRKENFELD AL, Bergman M, Stefan N
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2491-2492.
    PubMed    
    
    
    
37. JASTREBOFF AM, Ryan DH, Bays HE, Ebeling PR, et al
    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
    N Engl J Med. 2025 Jun 23. doi: 10.1056/NEJMoa2504214.
    PubMed     Abstract available
    
    
    
38. GARVEY WT, Bluher M, Osorto Contreras CK, Davies MJ, et al
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502081.
    PubMed     Abstract available
    
    
    
39. DAVIES MJ, Bajaj HS, Broholm C, Eliasen A, et al
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502082.
    PubMed     Abstract available
    
    
    May 2025
40. JI L, Jiang H, Bi Y, Li H, et al
    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMoa2411528.
    PubMed     Abstract available
    
    
    
41. ARODA VR, Perreault L
    Overweight and Obesity - Capturing the Whole Picture.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMe2505819.
    PubMed    
    
    
    
42. ARONNE LJ, Horn DB, le Roux CW, Ho W, et al
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
    N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394.
    PubMed     Abstract available
    
    
    
43. FOX CK, Harder-Lauridsen NM, Arslanian S
    Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.
    N Engl J Med. 2025;392:1868.
    PubMed    
    
    
    
44. EGAN JM, Kapogiannis D
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1868.
    PubMed    
    
    
    
45. JI C, Wang M
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1867.
    PubMed    
    
    
    
46. MALOZOWSKI S
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1867.
    PubMed    
    
    
    April 2025
47. PACKER M, Kramer CM, Borlaug BA
    Tirzepatide for Heart Failure and Obesity. Reply.
    N Engl J Med. 2025;392:1661-1662.
    PubMed    
    
    
    
48. ALI MK
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1661.
    PubMed    
    
    
    
49. MARINE JE, Mandrola J, Prasad V
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
50. KRAKAUER JC, Krakauer NY
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
51. WAGNER J
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1659-1660.
    PubMed    
    
    
    March 2025
52. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    November 2024
53. PACKER M, Zile MR, Kramer CM, Baum SJ, et al
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027.
    PubMed     Abstract available
    
    
    
54. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414470.
    PubMed    
    
    
    
55. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    October 2024
56. BLIDDAL H, Bays H, Czernichow S, Udden Hemmingsson J, et al
    Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
    N Engl J Med. 2024;391:1573-1583.
    PubMed     Abstract available
    
    
    
57. 
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024;391:1464.
    PubMed    
    
    
    September 2024
58. DRUCKER DJ
    Discovery of GLP-1-Based Drugs for the Treatment of Obesity.
    N Engl J Med. 2024 Sep 19. doi: 10.1056/NEJMcibr2409089.
    PubMed    
    
    
    
59. BARRETT T, Hamilton-Shield J
    Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMe2410560.
    PubMed    
    
    
    
60. FOX CK, Barrientos-Perez M, Bomberg EM, Dcruz J, et al
    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2407379.
    PubMed     Abstract available
    
    
    July 2024
61. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
62. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
63. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
64. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    June 2024
65. MALHOTRA A, Grunstein RR, Fietze I, Weaver TE, et al
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024 Jun 21. doi: 10.1056/NEJMoa2404881.
    PubMed     Abstract available
    
    
    
66. 
    Treating Obesity in Kids: ITT Episode 31.
    N Engl J Med. 2024;390:e52.
    PubMed    
    
    
    May 2024
67. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
68. EGAN JM
    Physiological Integration of Taste and Metabolism.
    N Engl J Med. 2024;390:1699-1710.
    PubMed    
    
    
    April 2024
69. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    February 2024
70. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
71. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
72. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
73. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
74. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
75. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
76. GORTMAKER SL, Bleich SN, Williams DR
    Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
    N Engl J Med. 2024;390:681-683.
    PubMed    
    
    
    
77. GOLOVATY I, Hagan S
    Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
    N Engl J Med. 2024;390:677-680.
    PubMed    
    
    
    December 2023
78. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
79. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
80. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
81. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    
82. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
83. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
84. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    November 2023
85. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
86. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    October 2023
87. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    
    
    
    
88. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    
    
    
    
89. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    
    
    
    
90. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    
    
    
    
91. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    
    
    
    
92. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    
    
    
    August 2023
93. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
94. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
95. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    
    
    
    July 2023
96. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    
    
    
    June 2023
97. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
98. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
99. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    
    
    
    
100. ROSEN CJ
     Antagonizing the Leptin Receptor in Obesity.
     N Engl J Med. 2023;388:2291-2293.
     PubMed    
     
     
     
101. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
     Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
     N Engl J Med. 2023;388:2253-2261.
     PubMed     Abstract available
     
     
     March 2023
102. WEGHUBER D, Kelly AS, Arslanian S
     Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
     N Engl J Med. 2023;388:1146.
     PubMed    
     
     
     
103. MALOZOWSKI S
     Once-Weekly Semaglutide in Adolescents with Obesity.
     N Engl J Med. 2023;388:1145-1146.
     PubMed    
     
     
     
104. SNAITH JR, Greenfield JR
     Once-Weekly Semaglutide in Adolescents with Obesity.
     N Engl J Med. 2023;388:1145.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum